Efalizumab

Efalizumab Suppliers list
Company Name: Beijing HuaMeiHuLiBiological Chemical   
Tel: 010-56205725
Email: waley188@sohu.com
Products Intro: Product Name:efalizuMab
CAS:339155-58-7
Purity:99% Package:25kg
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Efalizumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Company Name: A.T.CHEMICAL   
Tel: 0755-86655561 81899190
Email: Jeffreyxu@atchem.net
Products Intro:
Efalizumab Basic information
Product Name:Efalizumab
Synonyms:Efalizumab;Hu 1124;Raptiva;Unii-xx2mn88N5d;Xanelim
CAS:339155-58-7
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Efalizumab Structure
Efalizumab Chemical Properties
Safety Information
MSDS Information
Efalizumab Usage And Synthesis
UsesTreatment of transplant rejections; antipsoriatic (immunomodulator monoclonal antibody which decreases the activation, migration, and adhesion of T-cells). hu1124; anti-CD11a.
Efalizumab (Raptiva) is a humanized monoclonal antibody that binds to the CD11a subunit of LFA-1. It blocks the interaction of LFA-1 with ICAM-1, thereby interfering with T-cell activation and trafficking. Efalizumab is FDA approved at 1.0 mg/kg/week by subcutaneous injection. Common side effects include mild headache, fever, chills, nausea, or myalgia within the first 48 hours of injection in the first 2 to 3 weeks of therapy. Immune-mediated thrombocytopenia is rare. Worsening of psoriasis may occur after discontinuation of therapy or in unresponsive patients during therapy. Transitioning patients to alternative therapies may minimize this risk.
PharmacologyEfalizumab (Raptiva) is a humanized monoclonal antibody that binds to the CD11a subunit of LFA-1. It blocks the interaction of LFA-1 with ICAM-1, thereby interfering with T-cell activation and trafficking. Efalizumab is FDA approved at 1.0 mg/kg/week by subcutaneous injection.
Side effectsCommon side effects include mild headache, fever, chills, nausea, or myalgia within the first 48 hours of injection in the first 2 to 3 weeks of therapy. Immune-mediated thrombocytopenia is rare. Worsening of psoriasis may occur after discontinuation of therapy or in unresponsive patients during therapy. Transitioning patients to alternative therapies may minimize this risk.
Efalizumab Preparation Products And Raw materials
Tag:Efalizumab(339155-58-7) Related Product Information